358 related articles for article (PubMed ID: 16780833)
1. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
Eur J Pharmacol; 2007 Mar; 559(2-3):219-26. PubMed ID: 17250824
[TBL] [Abstract][Full Text] [Related]
3. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models.
Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
Eur J Pharmacol; 2006 Nov; 550(1-3):166-72. PubMed ID: 17010967
[TBL] [Abstract][Full Text] [Related]
5. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
7. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Houghton C; Sardar N; Withnall MT
Br J Pharmacol; 1997 Jun; 121(4):743-50. PubMed ID: 9208143
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
[TBL] [Abstract][Full Text] [Related]
11. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
14. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.
Aoki M; Kobayashi M; Ishikawa J; Saita Y; Terai Y; Takayama K; Miyata K; Yamada T
J Pharmacol Exp Ther; 2000 Oct; 295(1):255-60. PubMed ID: 10991987
[TBL] [Abstract][Full Text] [Related]
15. YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models.
Ohga K; Kuromitsu S; Takezawa R; Numazaki M; Ishikawa J; Nagashima S; Shimizu Y
Eur J Pharmacol; 2008 Aug; 590(1-3):409-16. PubMed ID: 18590722
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
17. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
[TBL] [Abstract][Full Text] [Related]
18. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
Cheng JB; Watson JW; Pazoles CJ; Eskra JD; Griffiths RJ; Cohan VL; Turner CR; Showell HJ; Pettipher ER
J Pharmacol Exp Ther; 1997 Feb; 280(2):621-6. PubMed ID: 9023272
[TBL] [Abstract][Full Text] [Related]
19. ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes.
Kadoshima-Yamaoka K; Murakawa M; Goto M; Tanaka Y; Inoue H; Murafuji H; Nagahira A; Hayashi Y; Nagahira K; Miura K; Nakatsuka T; Chamoto K; Fukuda Y; Nishimura T
Immunol Lett; 2009 Feb; 122(2):193-7. PubMed ID: 19195485
[TBL] [Abstract][Full Text] [Related]
20. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
